Riziero Abate-Esposito
Naples, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?
Journal: JCO precision oncology
Published: September 10, 2025
NONO Protein Regulates the Immune Response in Human Triple-Negative Breast Cancer Cells.
Journal: International journal of molecular sciences
Published: August 03, 2025
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.
Journal: Nature communications
Published: March 24, 2025
The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
Journal: International journal of molecular sciences
Published: April 05, 2024
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2024
Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2023
European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
Journal: International journal of molecular sciences
Published: August 02, 2023
Correction to: External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
Journal: Virchows Archiv : an international journal of pathology
Published: December 09, 2022
Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics.
Journal: Diagnostics (Basel, Switzerland)
Published: June 09, 2022
External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
Journal: Virchows Archiv : an international journal of pathology
Published: May 26, 2022
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
Journal: Journal for immunotherapy of cancer
Published: January 18, 2022
Last Updated: 09/26/2026